Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Scintigraphy Study of ALLN-346 Formulations in Healthy Volunteers
NCT05168683Phase 1Completed
- Sponsor
- Allena Pharmaceuticals, Inc.
- Start
- Jan 2022
- Primary completion
- Feb 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial of ALLN-346 in hyperuricemia and gout (2 cohorts), sponsored by Allena Pharmaceuticals, Inc. Primary endpoints: Gastrointestinal transit time of radiolabel release and Disintegration behavior of ALLN-346 formulations. Started Jan 2022; status: completed.
02
Drugs
ALLN-346
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT05168683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05168683.